Full Press Release Details
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Sub: Intimation of Earnings call
Please find enclosed a notification titled "Dr.
Reddy's to release Q3 results on January 30th, 2024, Earnings call slated for January 30th @ 7:30 PM IST / 10:00
This is for your information and records.
For Dr. Reddy's Laboratories Limited
| /s/ K Randhir Singh | |
| K Randhir Singh |
Company Secretary, Compliance Officer &
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, | Richa Periwal | USHA IYER |
| Hyderabad - 500034, Telangana, India. | richaperiwal@drreddys.com | ushaiyer@drreddys.com |
Reddy's to release Q3 results on January 30th, 2024
call slated for January 30th @ 7:30 PM IST / 10:00 AM EDT
Hyderabad, India, January 18th, 2024
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY,
NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31st, 2023 on Tuesday, January 30th,
2024 after the Board Meeting.
| Event | Date and Time | Medium |
| Release of financial results | January 30 th , after the Board Meeting | Stock Exchange, Media, Company website, Business wire, Email |
| Press meet presentation | Will be available on the Company's website | Company's website www.drreddys.com |
| Earnings Call | January 30 th , 7:30 PM IST / 10:00 AM EDT | Hosted by the Company (Details below) |
| Playback of Earnings Call | After the earnings call till February 6 th , 2024 | Details below |
| Transcript of the Earnings call | Will be available on the Company's website | Company's website www.drreddys.com |
Following the release, the management of the Company
will host Its earnings call to discuss the Company's financial performance. (Dial In and other details given below)
The play back will be available after the earnings
call, till February 6th, 2024. For play back dial in phone No: +91 22 7194 5757, and Playback Code is 61003.
Pre-register with the below link and join without waiting for the operator.
| Option 2: Join through below Dial-In Numbers | |
| Universal Access Number: | +91 22 6280 1219 +91 22 7115 8120 |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in
to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad,
India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Good
Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars
and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep
science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter
of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high
in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to:www.drreddys.com.
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general
economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition
and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the
impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets
addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics
or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings
with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"
sections of our Annual Report on Form 20-F for the year ended March 31, 2023. The company assumes no obligation to update any information
contained herein." The company assumes no obligation to update any information contained herein.